Bristol Myers: positive opinion from the CHMP for Opdivo
The European Commission (EC), which has the power to approve medicines for the European Union (EU), will now re-examine the CHMP recommendation. The EC's final decision is expected in June 2024.
With this positive CHMP opinion, 'we are one step closer to providing eligible patients with unresectable or metastatic urothelial carcinoma in the European Union with a new first-line treatment option', commented Dana Walker, Vice President and Global Program Leader, Genitourinary Cancers, Bristol Myers Squibb.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction